Optolab Card Diagnose
Diagnosing
AIDS, Disease Diagnosis, Paternity Test
The Ikerlan Centres
for Technological Research, connected to the Mondragon
Corporacion Cooperativa (MCC), has been selected
to lead the European Optolab Card project the
aim of which is to design and build up a device
for the quick and effective diagnosis in the treatment
and natural reduction of infectious diseases,
evermore present due to the high mobility of carriers.
The Ikerlan-led
project involves a device which is made up of
a portable base and a card that functions as a
laboratory and that automatically controls bacteria-provoked
health risks by means of real-time finding of
DNA - from sample preparation to visual detection.
There are various
technology centres from the Basque Country are
participating in the project such as Gaiker and
the Basque Foundation for Innovation and Research
in Healthcare (BIOEF), in addition to other centres
and companies from Germany, Sweden, Denmark ,Austria
and Poland. The project is due to last for 3 years
and it will take an additional three for the new
device to be on the market.
The optic laboratory
miniaturised on a card will detect salmonellosis,
the pathogen with the maximum incidence level
right through the European Union (40.7 persons
per 100,000 inhabitants). Moreover, the diagnostic
ability of the new device is very varied, being
able to detect and distinguish chains of DNA.
For example, it can able to detect other infectious
diseases such as tuberculosis,flu, hepatitis,
AIDS, etc.
Diagnosis
in 15 minutes
Another advantages
of the optic card laboratory is that it is the
first system to offer a rapid diagnosis of an
infectious disease within 15 minutes, given that
present analytical methods need a huge number
of samples and protocols that cause the tests
to take from 6 hours to 2 days to be carried out,
sufficient time for a whole community or a important
part of the population to turn out to be infected.
Possible upcoming
applications of the laboratory card are also highly
significant, as they can provide doctors with
devices for hereditary diagnosis for the early
detection of molecular diseases, such as degenerative
ones (Parkinson’s, Alzheimer and so on),
paternity tests, genetic disorders, as well as
forensic medicine applications.
The survival
of the laboratory card is also intended to significantly
improve the quality of the health system, minimizing
hospital admissions, the time exhausted in hospital
and costs relating to diagnoses. The request of
this device will have a great bearing on the minimizing
of infectious diseases.
This is not the
initial European project in which Ikerlan is involved.
This MCC-linked Centre for Technological Research
is at present developing new advanced systems
for the diagnosis of cancer, functioning together
with the Basque body Gaiker and BIOEF. This project,
relating a total of 11 countries, will last four
years. |